AU2005233382C1 - (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents - Google Patents
(Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents Download PDFInfo
- Publication number
- AU2005233382C1 AU2005233382C1 AU2005233382A AU2005233382A AU2005233382C1 AU 2005233382 C1 AU2005233382 C1 AU 2005233382C1 AU 2005233382 A AU2005233382 A AU 2005233382A AU 2005233382 A AU2005233382 A AU 2005233382A AU 2005233382 C1 AU2005233382 C1 AU 2005233382C1
- Authority
- AU
- Australia
- Prior art keywords
- naphtho
- hexahydrofuro
- oxo
- dioxol
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002360 preparation method Methods 0.000 title claims description 50
- 238000000034 method Methods 0.000 title claims description 46
- 230000008569 process Effects 0.000 title claims description 36
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 title claims description 16
- 239000003814 drug Substances 0.000 title claims description 15
- 239000002246 antineoplastic agent Substances 0.000 title claims description 8
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical class NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 156
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 105
- 206010028980 Neoplasm Diseases 0.000 claims description 57
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 33
- -1 alkyl radical Chemical class 0.000 claims description 29
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 125000006309 butyl amino group Chemical group 0.000 claims description 18
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 16
- 229960001237 podophyllotoxin Drugs 0.000 claims description 15
- 125000006308 propyl amino group Chemical group 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 14
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 13
- 150000003254 radicals Chemical group 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- 238000010520 demethylation reaction Methods 0.000 claims description 8
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 235000005985 organic acids Nutrition 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 230000017858 demethylation Effects 0.000 claims description 4
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- WNPUWXUTQILQOZ-UHFFFAOYSA-N n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]-2-piperidin-1-ylacetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CN3CCCCC3)C3C2C(OC3)=O)=C1 WNPUWXUTQILQOZ-UHFFFAOYSA-N 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003880 polar aprotic solvent Substances 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 239000002879 Lewis base Substances 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 241000863480 Vinca Species 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 238000011443 conventional therapy Methods 0.000 claims description 2
- 150000007527 lewis bases Chemical class 0.000 claims description 2
- VMRXJXYIJOWXRK-UHFFFAOYSA-N n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]-2-(2-morpholin-4-ylethylamino)acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CNCCN3CCOCC3)C3C2C(OC3)=O)=C1 VMRXJXYIJOWXRK-UHFFFAOYSA-N 0.000 claims description 2
- 150000003057 platinum Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- QMACERQVTLPWCM-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl-methylamino]-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CN(C)CCN(C)C)C3C2C(OC3)=O)=C1 QMACERQVTLPWCM-UHFFFAOYSA-N 0.000 claims 1
- YWVFNPGTEARBEO-UHFFFAOYSA-N 2-[2-(dimethylamino)ethylamino]-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CNCCN(C)C)C3C2C(OC3)=O)=C1 YWVFNPGTEARBEO-UHFFFAOYSA-N 0.000 claims 1
- NUZMJDHDPVKFJN-UHFFFAOYSA-N 2-[3-[4-(3-aminopropylamino)butylamino]propylamino]-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CNCCCNCCCCNCCCN)C3C2C(OC3)=O)=C1 NUZMJDHDPVKFJN-UHFFFAOYSA-N 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 238000002844 melting Methods 0.000 description 25
- 230000008018 melting Effects 0.000 description 25
- 239000000543 intermediate Substances 0.000 description 24
- 239000000460 chlorine Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 229910004298 SiO 2 Inorganic materials 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 238000006264 debenzylation reaction Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229960005420 etoposide Drugs 0.000 description 8
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- NJAPCAIWQRPQPY-UHFFFAOYSA-N benzyl hydrogen carbonate Chemical compound OC(=O)OCC1=CC=CC=C1 NJAPCAIWQRPQPY-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- YVCVYCSAAZQOJI-JHQYFNNDSA-N 4'-demethylepipodophyllotoxin Chemical class COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YVCVYCSAAZQOJI-JHQYFNNDSA-N 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 5
- FOVRGQUEGRCWPD-UHFFFAOYSA-N (5aR)-9t-beta-D-Glucopyranosyloxy-5t-(4-hydroxy-3,5-dimethoxy-phenyl)-(5ar,8at)-5,8,8a,9-tetrahydro-5aH-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-on Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(OC3C(C(O)C(O)C(CO)O3)O)C3C2C(OC3)=O)=C1 FOVRGQUEGRCWPD-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- DMFQNHALFAMFCE-UHFFFAOYSA-N 2-(1,3-dioxol-4-yl)acetamide Chemical compound NC(=O)CC1=COCO1 DMFQNHALFAMFCE-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 2
- FSIANMHCHLTQAP-UHFFFAOYSA-N 2-(dimethylamino)-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CN(C)C)C3C2C(OC3)=O)=C1 FSIANMHCHLTQAP-UHFFFAOYSA-N 0.000 description 2
- HABIVEFFFMNHTI-UHFFFAOYSA-N 2-chloro-n-[9-(3,4-dihydroxy-5-methoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound OC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CCl)C3C2C(OC3)=O)=C1 HABIVEFFFMNHTI-UHFFFAOYSA-N 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 238000006434 Ritter amidation reaction Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- VHTUJTDUGFVUGN-UHFFFAOYSA-N acetamide tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.C(C)(=O)N VHTUJTDUGFVUGN-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IZGKHHFFYLRBPL-UHFFFAOYSA-N benzyl n-(4-aminobutyl)carbamate Chemical compound NCCCCNC(=O)OCC1=CC=CC=C1 IZGKHHFFYLRBPL-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000003600 podophyllotoxin derivative Substances 0.000 description 2
- 229920000768 polyamine Chemical group 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000011806 swiss nude mouse Methods 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RNIWQCSFCFKJCS-UHFFFAOYSA-N 2-(4-aminobutylamino)-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CNCCCCN)C3C2C(OC3)=O)=C1 RNIWQCSFCFKJCS-UHFFFAOYSA-N 0.000 description 1
- HSAFSVXGDJWFBK-UHFFFAOYSA-N 2-(5-aminopentylamino)-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CNCCCCCN)C3C2C(OC3)=O)=C1 HSAFSVXGDJWFBK-UHFFFAOYSA-N 0.000 description 1
- GHBKKUSXBVBPCD-UHFFFAOYSA-N 2-(benzylamino)-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CNCC=3C=CC=CC=3)C3C2C(OC3)=O)=C1 GHBKKUSXBVBPCD-UHFFFAOYSA-N 0.000 description 1
- ITGUTPJYGQGXOA-UHFFFAOYSA-N 2-(butylamino)-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound C12=CC=3OCOC=3C=C2C(NC(=O)CNCCCC)C2COC(=O)C2C1C1=CC(OC)=C(O)C(OC)=C1 ITGUTPJYGQGXOA-UHFFFAOYSA-N 0.000 description 1
- NYHNJCRDDWHAQB-UHFFFAOYSA-N 2-(ethylamino)-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound C12=CC=3OCOC=3C=C2C(NC(=O)CNCC)C2COC(=O)C2C1C1=CC(OC)=C(O)C(OC)=C1 NYHNJCRDDWHAQB-UHFFFAOYSA-N 0.000 description 1
- AZINKBXNDIKXFW-UHFFFAOYSA-N 2-[3-(3-aminopropylamino)propylamino]-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CNCCCNCCCN)C3C2C(OC3)=O)=C1 AZINKBXNDIKXFW-UHFFFAOYSA-N 0.000 description 1
- UYIWMKHWVVWVNH-UHFFFAOYSA-N 2-[3-(4-aminobutylamino)propylamino]-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CNCCCNCCCCN)C3C2C(OC3)=O)=C1 UYIWMKHWVVWVNH-UHFFFAOYSA-N 0.000 description 1
- BQFWPHNMGVXQBH-UHFFFAOYSA-N 2-[4-(3-aminopropylamino)butylamino]-n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CNCCCCNCCCN)C3C2C(OC3)=O)=C1 BQFWPHNMGVXQBH-UHFFFAOYSA-N 0.000 description 1
- WZDBPQCRVZJXEN-UHFFFAOYSA-N 2-chloro-n-[8-oxo-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]acetamide Chemical compound COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CCl)C3C2C(OC3)=O)=C1 WZDBPQCRVZJXEN-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- WZBGSNYTODILNN-UHFFFAOYSA-N 5-hydroxy-9-(3,4,5-trihydroxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound C12=CC=3OCOC=3C=C2C(O)C2COC(=O)C2C1C1=CC(O)=C(O)C(O)=C1 WZBGSNYTODILNN-UHFFFAOYSA-N 0.000 description 1
- KDAVTDIQCUOJNV-UHFFFAOYSA-N 5a,8,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-6-one Chemical compound C1=C2CC3C(=O)OCC3CC2=CC2=C1OCO2 KDAVTDIQCUOJNV-UHFFFAOYSA-N 0.000 description 1
- KSJJGTZMFOIXEI-UHFFFAOYSA-N 6,8,8a,9-tetrahydro-5aH-[2]benzofuro[5,6-f][1,3]benzodioxol-5-one Chemical compound O=C1C2=CC3=C(OCO3)C=C2CC2C1COC2 KSJJGTZMFOIXEI-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- VIYBHGSKMKVEOH-UHFFFAOYSA-N NCCCC(CCC(=O)OCC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1 Chemical compound NCCCC(CCC(=O)OCC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1 VIYBHGSKMKVEOH-UHFFFAOYSA-N 0.000 description 1
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- LOYNQJUTFKXLDE-UHFFFAOYSA-N benzyl [4-(5-hydroxy-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-9-yl)-2,6-bis(phenylmethoxycarbonyloxy)phenyl] carbonate Chemical compound C12=CC=3OCOC=3C=C2C(O)C2COC(=O)C2C1C(C=C(OC(=O)OCC=1C=CC=CC=1)C=1OC(=O)OCC=2C=CC=CC=2)=CC=1OC(=O)OCC1=CC=CC=C1 LOYNQJUTFKXLDE-UHFFFAOYSA-N 0.000 description 1
- GPDNXBGJSKOINW-UHFFFAOYSA-N benzyl [4-(5-hydroxy-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-9-yl)-2-methoxy-6-phenylmethoxycarbonyloxyphenyl] carbonate Chemical compound C=1C=CC=CC=1COC(=O)OC=1C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=CC=1OC(=O)OCC1=CC=CC=C1 GPDNXBGJSKOINW-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- QMMFTRJQCCVPCE-UHFFFAOYSA-N benzyl n-(2-aminoethyl)carbamate Chemical compound NCCNC(=O)OCC1=CC=CC=C1 QMMFTRJQCCVPCE-UHFFFAOYSA-N 0.000 description 1
- KQBGVKWRPLVZAI-UHFFFAOYSA-N benzyl n-(3-aminopropyl)-n-[3-[phenylmethoxycarbonyl-[3-(phenylmethoxycarbonylamino)propyl]amino]propyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)N(CCCN)CCCN(C(=O)OCC=1C=CC=CC=1)CCCNC(=O)OCC1=CC=CC=C1 KQBGVKWRPLVZAI-UHFFFAOYSA-N 0.000 description 1
- UDTTZXPDZHTRBU-UHFFFAOYSA-N benzyl n-(3-aminopropyl)-n-[4-(phenylmethoxycarbonylamino)butyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)N(CCCN)CCCCNC(=O)OCC1=CC=CC=C1 UDTTZXPDZHTRBU-UHFFFAOYSA-N 0.000 description 1
- MARBZAYIWKDVGI-UHFFFAOYSA-N benzyl n-(4-aminobutyl)-n-[4-(phenylmethoxycarbonylamino)butyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)N(CCCCN)CCCCNC(=O)OCC1=CC=CC=C1 MARBZAYIWKDVGI-UHFFFAOYSA-N 0.000 description 1
- ZZRXQSABHQZWCC-UHFFFAOYSA-N benzyl n-(5-aminopentyl)carbamate Chemical compound NCCCCCNC(=O)OCC1=CC=CC=C1 ZZRXQSABHQZWCC-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229940047583 cetamide Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- SYHPANJAVIEQQL-UHFFFAOYSA-N dicarboxy carbonate Chemical class OC(=O)OC(=O)OC(O)=O SYHPANJAVIEQQL-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- QOHMWDJIBGVPIF-UHFFFAOYSA-N n',n'-diethylpropane-1,3-diamine Chemical compound CCN(CC)CCCN QOHMWDJIBGVPIF-UHFFFAOYSA-N 0.000 description 1
- URUTYRXPSWPAOH-UHFFFAOYSA-N n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]-2-(propylamino)acetamide Chemical compound C12=CC=3OCOC=3C=C2C(NC(=O)CNCCC)C2COC(=O)C2C1C1=CC(OC)=C(O)C(OC)=C1 URUTYRXPSWPAOH-UHFFFAOYSA-N 0.000 description 1
- DLFRTWDSGYBODC-UHFFFAOYSA-N n-[9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]-2-piperazin-1-ylacetamide Chemical compound COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(NC(=O)CN3CCNCC3)C3C2C(OC3)=O)=C1 DLFRTWDSGYBODC-UHFFFAOYSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0404053 | 2004-04-16 | ||
| FR0404053A FR2869035B1 (fr) | 2004-04-16 | 2004-04-16 | Derives (poly)aminoalkylaminoacetamide d'epipodophyllotoxine leur procede de preparation et leurs applications en therapeutique comme agent anticancereux |
| PCT/IB2005/001268 WO2005100363A1 (en) | 2004-04-16 | 2005-04-14 | (poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2005233382A1 AU2005233382A1 (en) | 2005-10-27 |
| AU2005233382B2 AU2005233382B2 (en) | 2009-07-16 |
| AU2005233382C1 true AU2005233382C1 (en) | 2010-02-04 |
Family
ID=34944659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005233382A Ceased AU2005233382C1 (en) | 2004-04-16 | 2005-04-14 | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7846926B2 (https=) |
| EP (1) | EP1742952B1 (https=) |
| JP (1) | JP4876070B2 (https=) |
| CN (1) | CN1946727B (https=) |
| AR (1) | AR048607A1 (https=) |
| AT (1) | ATE402938T1 (https=) |
| AU (1) | AU2005233382C1 (https=) |
| BR (1) | BRPI0509912B8 (https=) |
| CA (1) | CA2562617C (https=) |
| CY (1) | CY1108444T1 (https=) |
| DE (1) | DE602005008578D1 (https=) |
| DK (1) | DK1742952T3 (https=) |
| ES (1) | ES2311985T3 (https=) |
| FR (1) | FR2869035B1 (https=) |
| HR (1) | HRP20080542T3 (https=) |
| MX (1) | MXPA06011886A (https=) |
| MY (1) | MY137712A (https=) |
| PL (1) | PL1742952T3 (https=) |
| PT (1) | PT1742952E (https=) |
| RS (1) | RS50628B (https=) |
| SI (1) | SI1742952T1 (https=) |
| TW (1) | TWI350288B (https=) |
| WO (1) | WO2005100363A1 (https=) |
| ZA (1) | ZA200609055B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2888849B1 (fr) * | 2005-07-19 | 2007-10-05 | Pierre Fabre Medicament Sa | Procede de preparation de la 4b-amino-4'-demethyl-4-desoxypodophyllotoxine |
| FR2919287B1 (fr) * | 2007-07-26 | 2012-10-12 | Pf Medicament | Nouveaux derives fluorescents de polyamines, leur procede de preparation et leurs applications en tant qu'outils de diagnostic dans le traitement des tumeurs cancereuses. |
| FR2921369B1 (fr) * | 2007-09-25 | 2014-07-11 | Pf Medicament | Nouveau procede de preparation de derives (poly) aminoalkylaminoacetamide d'epipodophyllotoxine,utiles pour leurs applications en therapeutique comme agent anticancereux. |
| FR2921368B1 (fr) * | 2007-09-25 | 2012-10-12 | Pf Medicament | Nouveau procede de synthese de derives anticancereux de (poly) aminoalkylaminoacetamide d'epipodophyllotoxine. |
| FR2935143B1 (fr) * | 2008-08-19 | 2010-12-03 | Pf Medicament | Nouveaus derives (poly)aminoalkylaminoalkylamides, alkyl-urees, ou alkyl-sulfonamides d'epipodophyllotoxine, leur procede de preparation et leur application en therapeuthique comme agent cancereux |
| JP5731988B2 (ja) | 2008-12-31 | 2015-06-10 | ダブリュー・アール・グレイス・アンド・カンパニー−コネチカット | プロピレン系ポリマー、物品およびその製造プロセス |
| PL2373702T3 (pl) | 2008-12-31 | 2018-07-31 | W.R. Grace & Co.-Conn. | Kompozycja prekatalizatora z wewnętrznym donorem w postaci podstawionego aromatycznego diestru 1,2-fenylenowego oraz sposób |
| EP2507269B1 (en) | 2009-12-02 | 2014-10-29 | W.R. Grace & Co.-Conn. | Three and four atom bridged dicarbonate compounds as internal donors in catalysts for polypropylene manufacture |
| US8263520B2 (en) | 2009-12-02 | 2012-09-11 | Dow Global Technologies Llc | Two atom bridged dicarbonate compounds as internal donors in catalysts for polypropylene manufacture |
| CN102234283B (zh) * | 2010-04-23 | 2013-06-12 | 湖北工业大学 | 4′-去甲基表鬼臼毒素衍生物及其合成方法和应用 |
| EP2638047B1 (en) * | 2010-11-11 | 2014-07-16 | Council of Scientific and Industrial Research | "substituted 4-beta-acrylamidopodophyllotoxin congeners as antitumour antibiotics and the process for preparation thereof" |
| FR2967675B1 (fr) | 2010-11-24 | 2015-02-27 | Pf Medicament | Derives fluorescents de cyanines polyamines en tant que sonde de diagnostic |
| WO2015161745A1 (zh) * | 2014-04-25 | 2015-10-29 | 中国医药工业研究总院 | 鬼臼毒素衍生物、其制备方法、药物组合物及应用 |
| CN104926841A (zh) * | 2015-06-30 | 2015-09-23 | 遵义医学院 | 青蒿琥酯与鬼臼毒素偶联物在抗白血病药物中的应用及制备方法 |
| WO2018234574A1 (en) | 2017-06-22 | 2018-12-27 | Ygm Consult Sas | Combination therapy for the treatment of cancer |
| CN113801129A (zh) * | 2021-09-30 | 2021-12-17 | 大连民族大学 | 一种鬼臼毒素脂质衍生物、纳米载体及其制备方法和在肿瘤治疗中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6323884A (ja) * | 1986-07-17 | 1988-02-01 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
| US5300500A (en) * | 1989-02-23 | 1994-04-05 | The University Of North Carolina At Chapel Hill | 4 beta-amino podophyllotoxin analog compounds and methods |
| US5332811A (en) * | 1989-09-12 | 1994-07-26 | The University Of North Carolina At Chapel Hill | Etopside analogs |
| CN1068330A (zh) * | 1991-07-03 | 1993-01-27 | 国家医药管理局上海医药工业研究院 | 4-氮取代-4-脱氧-4′-去甲表鬼臼毒素衍生物及其合成方法 |
| FR2725990B1 (fr) * | 1994-10-21 | 1997-01-10 | Pf Medicament | Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux |
| FR2742439B1 (fr) | 1995-12-14 | 1998-03-06 | Pf Medicament | Procede de preparation de la 4'-demethylepipodophyllotoxine a partir de la podophyllotoxine |
| FR2810321B1 (fr) | 2000-06-20 | 2002-07-26 | Adir | Nouveaux derives de podophyllotoxine carbamate et thiocarbamate, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1377588B1 (en) | 2002-03-28 | 2005-08-10 | Council of Scientific and Industrial Research | 4-beta-1''-[(2''-(substituted benzoyl)anilino] podophyllotoxin analogues useful as anticancer agents |
| US6566393B1 (en) | 2002-06-21 | 2003-05-20 | The University Of North Carolina At Chapel Hill | Etoposide analogs and methods of use thereof |
| JP4920407B2 (ja) | 2003-02-14 | 2012-04-18 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 周辺組織の破壊が最小限で済む一様な電界を発生する電気外科的システム |
| US20070066837A1 (en) | 2003-02-18 | 2007-03-22 | Ahmed Kamal | Podophyllotoxin derivatives as antitumor agents |
-
2004
- 2004-04-16 FR FR0404053A patent/FR2869035B1/fr not_active Expired - Fee Related
-
2005
- 2005-04-09 MY MYPI20051581A patent/MY137712A/en unknown
- 2005-04-14 SI SI200530369T patent/SI1742952T1/sl unknown
- 2005-04-14 PT PT05734896T patent/PT1742952E/pt unknown
- 2005-04-14 CA CA2562617A patent/CA2562617C/en not_active Expired - Fee Related
- 2005-04-14 ES ES05734896T patent/ES2311985T3/es not_active Expired - Lifetime
- 2005-04-14 JP JP2007507869A patent/JP4876070B2/ja not_active Expired - Fee Related
- 2005-04-14 HR HR20080542T patent/HRP20080542T3/xx unknown
- 2005-04-14 WO PCT/IB2005/001268 patent/WO2005100363A1/en not_active Ceased
- 2005-04-14 MX MXPA06011886A patent/MXPA06011886A/es active IP Right Grant
- 2005-04-14 RS RSP-2008/0494A patent/RS50628B/sr unknown
- 2005-04-14 AU AU2005233382A patent/AU2005233382C1/en not_active Ceased
- 2005-04-14 PL PL05734896T patent/PL1742952T3/pl unknown
- 2005-04-14 DE DE602005008578T patent/DE602005008578D1/de not_active Expired - Lifetime
- 2005-04-14 EP EP05734896A patent/EP1742952B1/en not_active Expired - Lifetime
- 2005-04-14 DK DK05734896T patent/DK1742952T3/da active
- 2005-04-14 BR BRPI0509912A patent/BRPI0509912B8/pt not_active IP Right Cessation
- 2005-04-14 CN CN2005800123034A patent/CN1946727B/zh not_active Expired - Fee Related
- 2005-04-14 AT AT05734896T patent/ATE402938T1/de active
- 2005-04-14 US US11/578,266 patent/US7846926B2/en not_active Expired - Fee Related
- 2005-04-15 AR ARP050101486A patent/AR048607A1/es active IP Right Grant
- 2005-04-15 TW TW094111918A patent/TWI350288B/zh not_active IP Right Cessation
-
2006
- 2006-10-31 ZA ZA200609055A patent/ZA200609055B/en unknown
-
2008
- 2008-10-20 CY CY20081101164T patent/CY1108444T1/el unknown
-
2010
- 2010-11-10 US US12/943,804 patent/US9216989B2/en not_active Expired - Fee Related
-
2015
- 2015-09-01 US US14/842,068 patent/US9403840B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9403840B2 (en) | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | |
| EP2326653B1 (en) | New (poly)aminoalkylaminoalkyl-urea derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents | |
| AU2009275929B2 (en) | Nitrogenated derivatives of pancratistatin | |
| US20060247246A1 (en) | 9-Amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | |
| JP3909017B2 (ja) | ポドフィロトキシンカルバマートおよびチオカルバマート誘導体、その製造法、ならびにそれらを含有する医薬組成物 | |
| HK1095812B (en) | (poly) aminoacetamide derivatives of epipodophyllotoxin, their process of preparation and their applications in therapeutics as anticancer agents | |
| CN101233140B (zh) | 新的喜树碱类似物化合物、它们的制备方法以及含有它们的药用组合物 | |
| HK1154573A (en) | Nitrogenated derivatives of pancratistatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 SEP 2009. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 SEP 2009 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |